Drug:
Reaction: ILLNESS
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25113015 |
US |
2 | |
Illness, |
||||
BIMEKIZUMAB, |
||||
| 302 | 25113053 |
US |
1 | |
Illness, Cough, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 303 | 25113088 |
US |
2 | |
Illness, Headache, Fatigue, Myalgia, Pain in extremity, |
||||
BIMEKIZUMAB, OSELTAMIVIR PHOSPHATE, |
||||
| 304 | 25113149 |
US |
2 | |
Illness, |
||||
BIMEKIZUMAB, |
||||
| 305 | 25113196 |
US |
2 | |
Illness, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 306 | 25113219 |
GB |
2 | |
Illness, Product dose omission issue, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 307 | 25113245 |
US |
46 | 2 |
Illness, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 308 | 25113285 |
US |
2 | |
Illness, Product use issue, |
||||
BIMEKIZUMAB, |
||||
| 309 | 25113433 |
GB |
23 | 1 |
Illness, |
||||
RISANKIZUMAB-RZAA, |
||||
| 310 | 25113901 |
US |
36 | 2 |
Illness, |
||||
SPARSENTAN, |
||||
| 311 | 25114084 |
CA |
||
Abdominal pain upper, Angina unstable, Aphonia, Arthralgia, Blood pressure increased, Bronchitis, Cardiomegaly, Cellulitis, Cough, Diarrhoea, Drug hypersensitivity, Dysphonia, Dyspnoea exertional, Eczema, Erythema, Fall, Fatigue, Hypoaesthesia, Illness, Insomnia, Joint dislocation, Multiple fractures, Myalgia, Oropharyngeal pain, Pain, Pain in extremity, Phlebitis, Pneumonia, Productive cough, Pruritus, Pyrexia, Respiratory tract congestion, Secretion discharge, Shoulder fracture, Sputum discoloured, Thrombophlebitis, Thrombosis, Urinary tract infection, Wrong technique in product usage process, Urticaria, |
||||
ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, APIXABAN, FLUTICASONE PROPIONATE, MONTELUKAST, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, |
||||
| 312 | 25114147 |
US |
39 | 2 |
Cardiac operation, Illness, |
||||
TOFACITINIB, |
||||
| 313 | 25114193 |
US |
||
Pneumonia, COVID-19, Illness, Loss of consciousness, Wheezing, Lung disorder, Malaise, Drug ineffective, Product dose omission issue, Inappropriate schedule of product administration, |
||||
MEPOLIZUMAB, MEPOLIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ALENDRONATE SODIUM, CALCIUM, FLUTICASONE PROPIONATE AND SALMETEROL, LOSARTAN POTASSIUM, LOSARTAN, LEVOTHYROXINE, ROSUVASTATIN, ALENDRONATE SODIUM, ERGOCALCIFEROL, |
||||
| 314 | 25114359 |
US |
49 | 1 |
Illness, |
||||
DUPILUMAB, |
||||
| 315 | 25114393 |
US |
||
Illness, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 316 | 25114431 |
US |
1 | |
Illness, |
||||
DUPILUMAB, |
||||
| 317 | 25114510 |
US |
||
Illness, Coronavirus infection, Therapeutic response unexpected, |
||||
BELIMUMAB, |
||||
| 318 | 25114616 |
US |
39 | 2 |
Food poisoning, Illness, Fatigue, Pyrexia, Rebound eczema, Headache, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 319 | 25114678 |
US |
2 | |
Apparent death, Neoplasm malignant, Visual impairment, Illness, |
||||
ADALIMUMAB, |
||||
| 320 | 25114729 |
US |
64 | 2 |
Cervical spinal stenosis, Ear discomfort, Illness, Drug ineffective, |
||||
RIMEGEPANT SULFATE, |
||||
| 321 | 25115164 |
US |
2 | |
Loss of consciousness, Illness, Blood glucose increased, Product dose omission issue, |
||||
INSULIN GLARGINE, |
||||
| 322 | 25115173 |
US |
||
Surgery, Illness, |
||||
| 323 | 25118131 |
63 | 2 | |
Illness, Fatigue, Headache, |
||||
| 324 | 25118434 |
65 | 2 | |
Illness, |
||||
TOCILIZUMAB, |
||||
| 325 | 25118693 |
27 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 326 | 25118753 |
76 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 327 | 25119104 |
67 | 1 | |
Therapy interrupted, Illness, |
||||
ABATACEPT, |
||||
| 328 | 25109213 |
CA |
51 | 2 |
Asthma, Head injury, Illness, Respiratory syncytial virus infection, Influenza, Infection, Pneumonia, Dizziness, Dyspnoea, Fall, Inappropriate schedule of product administration, |
||||
GABAPENTIN, MEPOLIZUMAB, MEPOLIZUMAB, MEPOLIZUMAB, MEPOLIZUMAB, MODAFINIL, MONTELUKAST, OXYGEN, 0XYGEN, PREDNISONE, PREDNISONE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 329 | 25109236 |
US |
10 | 2 |
Abdominal pain upper, Influenza like illness, Pyrexia, Cough, Nasopharyngitis, Oxygen saturation decreased, Influenza, Illness, |
||||
CANAKINUMAB, CANAKINUMAB, CANAKINUMAB, CANAKINUMAB, |
||||
| 330 | 25107642 |
US |
57 | 2 |
Spinal operation, Illness, Rheumatoid arthritis, Illness, Osteoarthritis, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 331 | 25108018 |
US |
1 | |
Illness, |
||||
DUPILUMAB, |
||||
| 332 | 25108692 |
US |
80 | 2 |
Illness, Vision blurred, |
||||
INSULIN GLARGINE, |
||||
| 333 | 25108756 |
US |
1 | |
Illness, |
||||
RISANKIZUMAB-RZAA, |
||||
| 334 | 25108810 |
IE |
2 | |
Lower respiratory tract infection, Respiratory tract infection, Muscle spasms, Illness, |
||||
OCRELIZUMAB, |
||||
| 335 | 25108869 |
US |
65 | 2 |
Illness, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 336 | 25108877 |
US |
1 | |
Illness, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 337 | 25102602 |
US |
54 | 2 |
Illness, Malaise, |
||||
ALEMTUZUMAB, |
||||
| 338 | 25102627 |
US |
||
Illness, Adverse event, Withdrawal syndrome, Product substitution issue, |
||||
LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, |
||||
| 339 | 25102652 |
US |
1 | |
Lymphadenopathy, White blood cell count decreased, Illness, Off label use, |
||||
GABAPENTIN, |
||||
| 340 | 25102682 |
US |
1 | |
Cough, Sneezing, Illness, |
||||
DUPILUMAB, |
||||
| 341 | 25102751 |
US |
||
Drug ineffective, Infection, Memory impairment, Intentional product misuse, Product use issue, Device delivery system issue, Incorrect dose administered by device, Emergency care, Cough, Personality disorder, Illness, Fatigue, Product dose omission issue, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 342 | 25102889 |
US |
40 | |
Illness, Malaise, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 343 | 25102933 |
US |
41 | 1 |
Illness, Feeling abnormal, Depressed mood, Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND LAMIVUDINE, |
||||
| 344 | 25103031 |
US |
29 | 2 |
Illness, Product dose omission issue, Overdose, |
||||
SAPROPTERIN DIHYDROCHLORIDE, |
||||
| 345 | 25103138 |
US |
2 | |
Illness, Intentional dose omission, |
||||
PIMAVANSERIN TARTRATE, AMLODIPINE, DULOXETINE HYDROCHLORIDE, GABAPENTIN, LEUCOVORIN CALCIUM, METHOTREXATE, METHOTREXATE SODIUM, HYDROXYCHLOROQUINE SULFATE, CLOPIDOGREL, IXEKIZUMAB, TERIPARATIDE, FOLIC ACID, |
||||
| 346 | 25103142 |
US |
||
Hypotension, Dehydration, Illness, Influenza, Dizziness, Diarrhoea, |
||||
ACALABRUTINIB, |
||||
| 347 | 25103280 |
NL |
32 | 2 |
Illness, |
||||
PALIVIZUMAB, |
||||
| 348 | 25103282 |
NL |
32 | 1 |
Illness, |
||||
PALIVIZUMAB, |
||||
| 349 | 25103300 |
US |
||
Lymphadenopathy, Insomnia, Illness, Product dose omission issue, |
||||
BELIMUMAB, |
||||
| 350 | 25103558 |
BE |
63 | 2 |
Colitis, Illness, Constipation, Nasopharyngitis, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 351 | 25103750 |
CA |
54 | 2 |
Anxiety, Illness, Joint injury, Lower respiratory tract infection, Anaphylactic reaction, |
||||
ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, OXYCODONE, PREDNISONE, RABEPRAZOLE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, ETANERCEPT, FOLIC ACID, GOLD, METHOTREXATE SODIUM, SEMAGLUTIDE, |
||||
| 352 | 25103849 |
US |
83 | 2 |
Illness, |
||||
CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, |
||||
| 353 | 25103874 |
US |
72 | 1 |
Osteomyelitis, Illness, Hospitalisation, Pyrexia, |
||||
ADALIMUMAB, |
||||
| 354 | 25103880 |
US |
||
Illness, |
||||
| 355 | 25103903 |
US |
2 | |
Spinal compression fracture, Illness, Vomiting, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 356 | 25103956 |
US |
38 | 1 |
Illness, |
||||
TOBRAMYCIN, ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, DORNASE ALFA, |
||||
| 357 | 25104047 |
GB |
70 | 2 |
Illness, |
||||
CELECOXIB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 358 | 25104070 |
CA |
64 | 2 |
Abdominal pain upper, Arthralgia, Asthma, Autoimmune disorder, Back pain, Biliary colic, Blood pressure systolic increased, Chest pain, Cholecystitis, Confusional state, Cough, Dry mouth, Dyspnoea, Exposure to allergen, Fatigue, Feeling abnormal, Feeling cold, Feeling of body temperature change, Forced expiratory volume decreased, Gait disturbance, Gastroenteritis viral, Gingival recession, Headache, Heart rate increased, Hyperhidrosis, Illness, Inappropriate schedule of product administration, Inflammation, Influenza, Lumbar vertebral fracture, Middle insomnia, Migraine, Muscle spasms, Musculoskeletal stiffness, Nasopharyngitis, Nausea, Obstructive airways disorder, Oral disorder, Oropharyngeal pain, Pain, Pancreatitis, Pneumonia, Post procedural complication, Pyrexia, Therapeutic response decreased, Type 2 diabetes mellitus, Vomiting, Weight decreased, Weight increased, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, MORPHINE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, BUDESONIDE, BUDESONIDE, CANDESARTAN, CANDESARTAN, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CLONIDINE, CLONIDINE, CLOZAPINE, CYCLOBENZAPRINE, CYCLOBENZAPRINE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PREDNISONE, PREDNISONE, PREDNISONE, MONTELUKAST SODIUM, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 359 | 25104164 |
US |
1 | |
Illness, |
||||
MEPOLIZUMAB, |
||||
| 360 | 25104583 |
US |
||
Illness, |
||||
TIRZEPATIDE, |
||||
| 361 | 25104653 |
US |
2 | |
Illness, Pyrexia, Muscle spasms, Dyspnoea, |
||||
SECUKINUMAB, |
||||
| 362 | 25104886 |
44 | 2 | |
Illness, |
||||
UPADACITINIB, |
||||
| 363 | 25104941 |
US |
60 | 2 |
Swelling, Oedema, Gait disturbance, Illness, Feeling abnormal, Pain, Asthenia, Drug ineffective, Fatigue, Headache, Dyspnoea, Dyspepsia, |
||||
TADALAFIL, |
||||
| 364 | 25105005 |
CA |
74 | 2 |
Condition aggravated, Cough, Decreased appetite, Fall, Fatigue, Haemorrhoids, Illness, Malaise, Peripheral swelling, Weight decreased, Off label use, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, LANREOTIDE ACETATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, EVEROLIMUS, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, OCTREOTIDE ACETATE, OCTREOTIDE, ROSUVASTATIN, |
||||
| 365 | 25105145 |
US |
||
Illness, Asthma, Influenza, Dyspnoea, Drug dose omission by device, Device delivery system issue, Product quality issue, Device mechanical issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 366 | 25105231 |
US |
1 | |
Influenza, Illness, |
||||
BUPRENORPHINE, |
||||
| 367 | 25105284 |
CA |
1 | |
Pneumonia, Immunosuppression, Pharyngitis, Rhinitis, Swollen joint count increased, Illness, Therapy partial responder, |
||||
SECUKINUMAB, |
||||
| 368 | 25105393 |
US |
1 | |
Abdominal discomfort, Illness, |
||||
CARBOPLATIN, ETOPOSIDE, |
||||
| 369 | 25105454 |
US |
38 | 2 |
Illness, |
||||
TOFACITINIB, |
||||
| 370 | 25105471 |
US |
||
Illness, |
||||
PANTOPRAZOLE SODIUM, HYDROXYCHLOROQUINE SULFATE, LEVOTHYROXINE SODIUM, |
||||
| 371 | 25105476 |
US |
55 | 2 |
Illness, Cough, Product prescribing error, |
||||
TOFACITINIB, TOFACITINIB, |
||||
| 372 | 25105531 |
US |
2 | |
Illness, |
||||
BEMPEDOIC ACID, EVOLOCUMAB, |
||||
| 373 | 25105872 |
US |
2 | |
Vocal cord dysfunction, Infection, Headache, Illness, Vocal cord paresis, Condition aggravated, |
||||
| 374 | 25105953 |
US |
66 | 1 |
Illness, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 375 | 25106565 |
US |
2 | |
Breast operation, Abscess, Irritable bowel syndrome, Fibromyalgia, Endometriosis, Illness, |
||||
RISANKIZUMAB-RZAA, |
||||
| 376 | 25106643 |
US |
1 | |
Therapy interrupted, Illness, |
||||
APREMILAST, |
||||
| 377 | 25106767 |
US |
1 | |
Incorrect dose administered, Illness, |
||||
CANAKINUMAB, CANAKINUMAB, |
||||
| 378 | 25106857 |
US |
2 | |
Illness, Aphonia, |
||||
OFATUMUMAB, |
||||
| 379 | 25106937 |
US |
2 | |
Suicide attempt, Angina pectoris, Loss of consciousness, Overdose, Drug dependence, Drug abuse, Illness, Night sweats, Muscle spasms, Physical disability, Stress, Psychiatric symptom, Impaired quality of life, Tooth injury, Nervous system disorder, Behavioural addiction, Injury, Pyrexia, Emotional distress, Drug diversion, Product prescribing issue, Drug withdrawal syndrome, |
||||
OXYCODONE HYDROCHLORIDE, BUPRENORPHINE, BUPRENORPHINE, MORPHINE SULFATE, HYDROMORPHONE HYDROCHLORIDE, MORPHINE SULFATE, HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ZOLPIDEM TARTRATE, |
||||
| 380 | 25106947 |
US |
||
Pyrexia, Illness, |
||||
SAPROPTERIN DIHYDROCHLORIDE, |
||||
| 381 | 25107590 |
US |
2 | |
Infusion site haemorrhage, Infusion site pain, Infusion site swelling, Illness, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, SELEXIPAG, KETAMINE HYDROCHLORIDE, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, CLONIDINE, KETOPROFEN, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, AMITRIPTYLINE HYDROCHLORIDE, GABAPENTIN, SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, MACITENTAN, |
||||
| 382 | 25107608 |
US |
2 | |
Off label use, Hip surgery, Illness, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 383 | 25112012 |
1 | ||
Illness, Fungal infection, Pyrexia, |
||||
AMBRISENTAN, RIOCIGUAT, |
||||
| 384 | 25112320 |
|||
Illness, Therapy interrupted, |
||||
OCRELIZUMAB, |
||||
| 385 | 25113129 |
72 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 386 | 25113132 |
38 | 1 | |
Illness, |
||||
ETANERCEPT, |
||||
| 387 | 25113371 |
40 | 1 | |
Illness, |
||||
ADALIMUMAB, |
||||
| 388 | 25113372 |
49 | 2 | |
Illness, Vomiting, |
||||
ADALIMUMAB, |
||||
| 389 | 25113377 |
59 | 2 | |
Illness, |
||||
ADALIMUMAB, |
||||
| 390 | 25113379 |
51 | 2 | |
Illness, Therapy interrupted, |
||||
ADALIMUMAB, ADALIMUMAB, |
||||
| 391 | 25113777 |
62 | 2 | |
Illness, |
||||
ABATACEPT, |
||||
| 392 | 25113788 |
38 | 2 | |
Illness, |
||||
ABATACEPT, |
||||
| 393 | 25097410 |
LT |
50 | 2 |
Condition aggravated, Disease progression, Drug ineffective, Illness, Ileus, Vomiting, Abdominal pain, Oral fungal infection, |
||||
CARBOPLATIN, TOPOTECAN, |
||||
| 394 | 25097586 |
US |
71 | 2 |
Eczema, Illness, |
||||
DUPILUMAB, RISANKIZUMAB-RZAA, |
||||
| 395 | 25097729 |
US |
59 | 2 |
Sinusitis, Urinary tract infection, Hypersomnia, Seasonal allergy, Fungal infection, Multiple allergies, Back pain, Infusion site haemorrhage, Headache, Fatigue, Diarrhoea, Myalgia, Dyspnoea, Dizziness, Upper respiratory tract infection, COVID-19, Illness, Insurance issue, Product use issue, |
||||
PREDNISONE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, FUROSEMIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, ALBUTEROL SULFATE, EPINEPHRINE, ADRENALINUM, FLUTICASONE PROPIONATE, AMLODIPINE BESYLATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, AMITRIPTYLINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, VALSARTAN, TIZANIDINE HYDROCHLORIDE, LIDOCAINE, |
||||
| 396 | 25097902 |
DE |
1 | |
Neoplasm malignant, Renal failure, Illness, |
||||
SACUBITRIL AND VALSARTAN, |
||||
| 397 | 25098010 |
US |
77 | 2 |
Carpal tunnel syndrome, Illness, Product use issue, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, |
||||
| 398 | 25098032 |
CA |
54 | 2 |
Anxiety, Illness, Joint injury, Lower respiratory tract infection, Anaphylactic reaction, |
||||
SEMAGLUTIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE ALLERGY, ETANERCEPT, FOLIC ACID, GOLD, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METHOTREXATE SODIUM, OXYCODONE, PREDNISONE, RABEPRAZOLE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, |
||||
| 399 | 25098073 |
US |
2 | |
Illness, |
||||
DUPILUMAB, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, MONTELUKAST SODIUM, MONTELUKAST, PREDNISONE, TIOTROPIUM BROMIDE, |
||||
| 400 | 25098087 |
US |
||
Illness, |
||||
TIRZEPATIDE, SEMAGLUTIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28